Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edratide - XTL Biopharmaceuticals

Drug Profile

Edratide - XTL Biopharmaceuticals

Alternative Names: hCDR1; TV-4710

Latest Information Update: 01 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Teva Pharmaceutical Industries; XTL Biopharmaceuticals
  • Class Peptides
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Preclinical Sjogren's syndrome

Most Recent Events

  • 27 Nov 2017 XTL Biopharmaceuticals plans a phase II trial for Systemic lupus erythematosus
  • 12 Sep 2017 XTL Biopharmaceuticals files for a third patent application with the US Patent and Trademark Office (USPTO) for edratide in USA
  • 16 Jun 2017 Preclinical trials in Sjogren's syndrome in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top